Source: FDA, National Drug Code (US) Revision Year: 2018
None.
Topical corticosteroids, including CUTIVATE Lotion, can produce reversible HPA axis suppression with the potential for glucocorticoid insufficiency. Risk factors that predispose to HPA axis suppression include the use of high-potency topical corticosteroids, large treatment surface areas, prolonged use, use under occlusion, concomitant use of more than one corticosteroid-containing product, altered skin barrier, and liver failure. Pediatric patients may be at greater risk of HPA axis suppression due to their higher skin surface area to body mass ratios [see Use in Specific Populations (8.4)].
HPA axis suppression may occur during or after withdrawal of treatment. If HPA axis suppression is suspected, gradually withdraw the drug, reduce the frequency of application, or substitute a less potent topical corticosteroid. Evaluation of HPA axis suppression may be done by using the cosyntropin stimulation test.
The effects of CUTIVATE Lotion on HPA axis function in pediatric patients were investigated in two trials. Among a total of 89 evaluable subjects from the two trials who were treated with CUTIVATE Lotion twice daily for 3 to 4 weeks, a single subject with >90% body surface area treated showed laboratory evidence of transient suppression immediately post-treatment. The post cosyntropin stimulation test serum cortisol returned to a normal level (22.1µg/dL) within one week of the final treatment visit [see Use In Specific Populations (8.4) and Clinical Pharmacology (12.2)].
Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids.
Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids.
CUTIVATE Lotion may cause local adverse reactions, including skin atrophy [see Adverse Reactions (6.1, 6.2)]. The risk is greater with use under occlusion and with higher potency products.
CUTIVATE Lotion contains the excipient imidurea which releases formaldehyde as a breakdown product. Formaldehyde may cause allergic sensitization or irritation upon contact with the skin. Avoid using CUTIVATE Lotion in individuals with hypersensitivity to formaldehyde as it may prevent healing or worsen dermatitis.
If irritation develops, discontinue CUTIVATE Lotion and institute appropriate therapy.
Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noticing a clinical exacerbation. Such an observation can be corroborated with appropriate diagnostic patch testing. Discontinue CUTIVATE Lotion if appropriate.
If skin infections are present or develop at the treatment site, an appropriate antimicrobial agent should be used. If a favorable response does not occur promptly, discontinue use of CUTIVATE Lotion until the infection has been adequately controlled.
The following adverse reactions are discussed in greater detail in other sections of the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In 2 multicenter vehicle-controlled clinical trials of once-daily application of CUTIVATE Lotion by 196 adult and 242 pediatric patients, the total incidence of adverse reactions considered drug related by investigators was approximately 4%. These were local cutaneous reactions, usually mild and self-limiting, and consisted primarily of burning/stinging (2%). All other drug-related events occurred with an incidence of less than 1%, and included were contact dermatitis, exacerbation of atopic dermatitis, folliculitis of legs, pruritus, pustules on arm, rash, and skin infection. See Table 1.
The incidence of adverse reactions between the 242 pediatric subjects (age 3 months to <17 years) and 196 adult subjects (17 years or older) was similar (4% and 5%, respectively).
Table 1. Adverse Reactions from Controlled Clinical Trials (n=438):
| ADVERSE REACTIONS | CUTIVATE Lotion | VEHICLE |
|---|---|---|
| n=221 | n=217 | |
| Burning/Stinging skin | 4 (2%) | 3 (1%) |
| Contact Dermatitis | 0 | 1 (<1%) |
| Exacerbation of Atopic dermatitis | 0 | 1 (<1%) |
| Folliculitis of legs | 2 (<1%) | 0 |
| Irritant Contact Dermatitis | 0 | 1 (<1%) |
| Pruritus | 1 (<1%) | 1 (<1%) |
| Pustules on Arms | 1 (<1%) | 0 |
| Rash | 1 (<1%) | 2 (<1%) |
| Skin Infection | 0 | 3 (1%) |
During the clinical trials, eczema herpeticum occurred in a 33-year old male patient treated with CUTIVATE Lotion.
Table 2 summarizes all adverse events by body system that occurred in at least 1% of patients in either the drug or vehicle group in the phase 3 controlled clinical trials.
Table 2. Adverse Events Occurring in ≥1% of Patients from Either Arm from Controlled Clinical Trials (n=438):
| Body System | CUTIVATE Lotion | Vehicle Lotion |
|---|---|---|
| n=221 | n=217 | |
| Any Adverse Event | 77 (35%) | 82 (38%) |
| Skin | ||
| Burning and Stinging | 4 (2%) | 3 (1%) |
| Pruritus | 3 (1%) | 5 (2%) |
| Rash | 2 (<1%) | 3 (1%) |
| Skin Infection | 0 | 3 (1%) |
| Ear, Nose, Throat | ||
| Common Cold | 9 (4%) | 5 (2%) |
| Ear Infection | 3 (1%) | 3 (1%) |
| Nasal Sinus Infection | 2 (<1%) | 4 (2%) |
| Rhinitis | 1 (<1%) | 3 (1%) |
| Upper Respiratory Tract Infection | 6 (3%) | 7 (3%) |
| Gastrointestinal | ||
| Normal Tooth Eruption | 2 (<1%) | 3 (1%) |
| Diarrhea | 3 (1%) | 0 |
| Vomiting | 3 (1%) | 2 (<1%) |
| Lower Respiratory | ||
| Cough | 7 (3%) | 6 (3%) |
| Influenza | 5 (2%) | 0 |
| Wheeze | 0 | 3 (1%) |
| Neurology | ||
| Headache | 4 (2%) | 5 (2%) |
| Non-Site Specific | ||
| Fever | 8 (4%) | 8 (4%) |
| Seasonal Allergy | 2 (<1%) | 3 (1%) |
In an open label HPA axis suppression trial of 44 pediatric subjects (ages ≥3 months to ≤6 years) CUTIVATE Lotion was applied twice daily (rather than the indicated dosing regimen of once daily) to at least 35% of body surface area for 3 or 4 weeks. Subjects whose lesions cleared after 2 or 3 weeks of treatment continued to apply CUTIVATE Lotion for an additional week. The overall incidence of adverse reactions was 14%. These were local, cutaneous reactions and included dry skin (7%), stinging at application site (5%), and excoriation (2%). Additionally, a 4-month-old patient treated with CUTIVATE Lotion had marked elevations of the hepatic enzymes AST and ALT [See Use in Specific Populations (8.4)].
In another open label HPA axis suppression trial in which CUTIVATE Lotion was also applied twice daily (rather than the indicated dosing regimen of once daily), 56 pediatric subjects (ages ≥3 months to 12 months), were enrolled [see Use in Specific Populations (8.4)].
The adverse reactions included 2 cases of Herpes simplex at the application site (3.6%) and 3 cases of bacterial skin infections (5.4%).
The following local adverse reactions have been identified during post-approval use of CUTIVATE Lotion: erythema, edema/swelling, and bleeding.
The following systemic adverse reactions have been identified during post-approval use of CUTIVATE Cream and CUTIVATE Ointment: immunosuppression/Pneumocystis jirovecii pneumonia/leukopenia/thrombocytopenia; hyperglycemia/glycosuria; Cushing syndrome; generalized body edema/blurred vision; and acute urticarial reaction (edema, urticaria, pruritus, and throat swelling).
The following local adverse reactions have also been reported with the use of topical corticosteroids, and they may occur more frequently with the use of occlusive dressings or higher potency corticosteroids. These reactions include: acneiform eruptions, hypopigmentation, perioral dermatitis, skin atrophy, striae, hypertrichosis and miliaria.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Pregnancy Category C
There are no adequate and well-controlled studies in pregnant women. Therefore, CUTIVATE Lotion should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Systemic embryofetal development studies were conducted in mice, rats and rabbits.
Subcutaneous doses of 15, 45 and 150 μg/kg/day of fluticasone propionate were administered to pregnant female mice from gestation days 6 to 15. A teratogenic effect characteristic of corticosteroids (cleft palate) was noted after administration of 45 and 150 μg/kg/day (less than the MRHD in adults based on body surface area comparisons) in this study. No treatment related effects on embryofetal toxicity or teratogenicity were noted at 15 μg/kg/day (less than the MRHD in adults based on body surface area comparisons).
Subcutaneous doses of 10, 30 and 100 μg/kg/day of fluticasone propionate were administered to pregnant female rats in two embryofetal development studies (one study administered fluticasone propionate from gestation days 6 to 15 and the other study from gestation days 7 to 17). In the presence of maternal toxicity, fetal effects noted at 100 μg/kg/day (less than the MRHD in adults based on body surface area comparisons) included decreased fetal weights, omphalocele, cleft palate, and retarded skeletal ossification. No treatment related effects on embryofetal toxicity or teratogenicity were noted at 10 μg/kg/day (less than the MRHD in adults based on body surface area comparisons).
Subcutaneous doses of 0.08, 0.57 and 4 μg/kg/day of fluticasone propionate were administered to pregnant female rabbits from gestation days 6 to 18. Fetal effects noted at 4 μg/kg/day (less than the MRHD in adults based on body surface area comparisons) included decreased fetal weights, cleft palate and retarded skeletal ossification. No treatment related effects on embryofetal toxicity or teratogenicity were noted at 0.57 μg/kg/day (less than the MRHD in adults based on body surface area comparisons).
Oral doses of 3, 30 and 300 μg/kg/day fluticasone propionate were administered to pregnant female rabbits from gestation days 8 to 20. No fetal or teratogenic effects were noted at oral doses up to 300 μg/kg/day (less than the MRHD in adults based on body surface area comparisons) in this study. However, no fluticasone propionate was detected in the plasma in this study, consistent with the established low bioavailability following oral administration.
Fluticasone propionate crossed the placenta following administration of a subcutaneous or an oral dose of 100 μg/kg tritiated fluticasone propionate to pregnant rats.
Systemically administered corticosteroids appear in human milk and can suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when CUTIVATE Lotion is administered to a nursing woman.
CUTIVATE Lotion may be used in pediatric patients as young as 3 months of age. The safety and effectiveness of CUTIVATE Lotion in pediatric patients below 3 months of age have not been established.
Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of systemic effects when treated with topical drugs. They are, therefore, also at greater risk of HPA axis suppression and adrenal insufficiency upon the use of topical corticosteroids [see Warnings and Precautions (5.1)].
In an HPA axis suppression trial, none of the 40 evaluable pediatric subjects, 4 months old to <6 years old, with moderate to severe atopic dermatitis covering ≥ 35% Body Surface Area (BSA) who were treated with an exaggerated dosing regimen (twice daily) of CUTIVATE Lotion experienced adrenal suppression (defined as a 30-minute post-stimulation cortisol level ≤18 micrograms/dL) [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2)].
In another HPA axis suppression trial, one of 49 (2%) evaluable pediatric subjects, 3 months to 11 months old, with moderate to severe atopic dermatitis covering ≥35% Body Surface Area (BSA) who applied an exaggerated dosing regimen (twice daily) of CUTIVATE Lotion experienced reversible adrenal suppression (defined as a 30-minute post-stimulation cortisol level ≤18 micrograms/dL) following 4 weeks of therapy [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2)].
Systemic effects such as Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients, especially those with prolonged exposure to large doses of high-potency topical corticosteroids, or concomitant use of more than one corticosteroid product.
Local adverse reactions including skin atrophy have also been reported with use of topical corticosteroids in pediatric patients.
Parents of pediatric patients should be advised not to use this medication in the treatment of diaper dermatitis unless directed by a physician. CUTIVATE Lotion should not be applied in the diaper areas as diapers or plastic pants may constitute occlusive dressing.
A limited number of patients above 65 years of age have been treated with CUTIVATE Lotion in US and non-US clinical trials. Specifically only 8 patients above 65 years of age were treated with CUTIVATE Lotion in controlled clinical trials. The number of patients is too small to permit separate analyses of efficacy and safety.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
